ADMA Biologics Inc Stock News

Zacks Investment Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $1.50 price objective on the biotechnology companys stock. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and []

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and

Zacks Investment Research lowered shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious []

Zacks Investment Research lowered shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. []

The trading price of ADMA Biologics Inc. (NASDAQ:ADMA) closed lower on Monday, December 13, closing at $1.30, -2.26% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Goldman Sachs Group Inc. reduced its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 62.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,805 shares of the biotechnology companys stock after selling 232,591 shares during the period. Goldman Sachs Group Inc. [] The post Goldman Sachs Group Inc. Sells 232,591 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) appeared first on ETF Daily News .

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Community Health Systems' (CYH) cost-control initiatives are likely to lower costs to a great extent and boost the bottom line.

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin

Given this backdrop, investors likely want to consider adding stocks in December and heading into 2022. Today, we utilized a Zacks screen to find highly-ranked stocks trading for under $10 a share...

Given this backdrop, investors likely want to consider adding stocks in December and heading into 2022. Today, we utilized a Zacks screen to find highly-ranked stocks trading for under $10 a share.

Zacks Investment Research downgraded shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a research report report published on Thursday morning, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of []

Zacks Investment Research cut shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of []

Meridian Wealth Management LLC lifted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 206,000 shares of the biotechnology companys stock after acquiring an additional 42,000 shares during the period. Meridian Wealth []